valproic acid has been researched along with Huntington Disease in 34 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chorea in Huntington's Disease (HD) is usually treated with antidopaminergic neuroleptics like haloperidol, olanzapine and tiaprid or dopamine depleting drugs like tetrabenazine." | 2.72 | Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series. ( Andrich, JE; Kraus, PH; Lauter, T; Przuntek, H; Saft, C, 2006) |
| "In a single-case study of Huntington's Chorea the effect of sodium valproate on motor behaviour was first compared with that of L-Dopa and than investigated further alone." | 2.64 | Sodium valproate in Huntington's chorea. ( Leijnse-Ybema, HJ; Tan, BK; Zee, MF, 1976) |
| "Using Alzheimer's disease and Huntington's disease as examples in the following article, some of latest data linking both the histone code and the various proteins that regulate this code to the pathogenesis of neurological disease are discussed." | 2.47 | Epigenetic treatment of neurological disease. ( Gray, SG, 2011) |
| "Among psychiatric disorders the acute symptoms of schizophrenia are exacerbated by enhanced GABA-ergic function." | 2.36 | Pharmacology of GABA. ( Meldrum, B, 1982) |
| "Treatment with rosiglitazone (5, 10 mg/kg) and VPA (100, 200 mg/kg) for 21 days significantly attenuated these behavioral, biochemical, and cellular alterations as compared to control (QA 200 nmol) group." | 1.40 | Rosiglitazone synergizes the neuroprotective effects of valproic acid against quinolinic acid-induced neurotoxicity in rats: targeting PPARγ and HDAC pathways. ( Chaudhary, T; Kumar, A; Mishra, J, 2014) |
| " Furthermore, long-term administration (over a year) of high doses of the agent (up to 2,400 mg per day; 92 mg per kilogram per day) did not seem to alter the slow progression of their disease." | 1.26 | Long-term treatment of juvenile Huntington's chorea with dipropylacetic acid. ( Bachman, DS; Butler, IJ; McKhann, GM, 1977) |
| "Treatment with haloperidol in all patients and with dipropylacetic acid in three patients did not appear to modify the CSF, HVA, and 5HIAA concentrations, the plasma DBH activity, or the DA uptake." | 1.26 | Biochemical aspects of Huntington's chorea. ( Algeri, S; Branciforti, A; Calderini, G; Caraceni, T; Consolazione, A; Dall'olio, A; Girotti, F; Morselli, PL; Riva, E; Spreafico, R, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (50.00) | 18.7374 |
| 1990's | 1 (2.94) | 18.2507 |
| 2000's | 7 (20.59) | 29.6817 |
| 2010's | 9 (26.47) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Williams, A | 1 |
| Sarkar, S | 1 |
| Cuddon, P | 1 |
| Ttofi, EK | 1 |
| Saiki, S | 1 |
| Siddiqi, FH | 1 |
| Jahreiss, L | 1 |
| Fleming, A | 1 |
| Pask, D | 1 |
| Goldsmith, P | 1 |
| O'Kane, CJ | 1 |
| Floto, RA | 1 |
| Rubinsztein, DC | 1 |
| Whiting, WL | 1 |
| Velasco, R | 1 |
| Stewart, JT | 1 |
| Mishra, J | 1 |
| Chaudhary, T | 1 |
| Kumar, A | 1 |
| Lin, F | 1 |
| Qin, ZH | 1 |
| Linares, GR | 1 |
| Chiu, CT | 2 |
| Scheuing, L | 1 |
| Leng, Y | 1 |
| Liao, HM | 1 |
| Maric, D | 1 |
| Chuang, DM | 2 |
| Salazar, Z | 1 |
| Tschopp, L | 1 |
| Calandra, C | 1 |
| Micheli, F | 1 |
| Cowell, RM | 1 |
| Talati, P | 1 |
| Blake, KR | 1 |
| Meador-Woodruff, JH | 1 |
| Russell, JW | 1 |
| Zádori, D | 1 |
| Geisz, A | 1 |
| Vámos, E | 1 |
| Vécsei, L | 1 |
| Klivényi, P | 1 |
| El-Akabawy, G | 1 |
| Medina, LM | 1 |
| Jeffries, A | 1 |
| Price, J | 1 |
| Modo, M | 1 |
| Liu, G | 1 |
| Leeds, P | 1 |
| Tallaksen-Greene, SJ | 1 |
| Albin, RL | 1 |
| Gray, SG | 1 |
| Cuturic, M | 1 |
| Abramson, RK | 1 |
| Moran, RR | 1 |
| Hardin, JW | 1 |
| Frank, EM | 1 |
| Sellers, AA | 1 |
| Saft, C | 1 |
| Lauter, T | 1 |
| Kraus, PH | 1 |
| Przuntek, H | 1 |
| Andrich, JE | 1 |
| Tremolizzo, L | 1 |
| Rodriguez-Menendez, V | 1 |
| DiFrancesco, JC | 1 |
| Sala, G | 1 |
| Galbussera, A | 1 |
| Appollonio, I | 1 |
| Ferrarese, C | 1 |
| Previdi, P | 1 |
| Borgonovi, R | 1 |
| Meldrum, B | 1 |
| Puca, FM | 1 |
| Genco, S | 1 |
| Minervini, MG | 1 |
| Specchio, LM | 1 |
| Napoletano, V | 1 |
| Brancasi, B | 1 |
| Reggio, F | 1 |
| Marsden, CD | 1 |
| Sheehy, MP | 1 |
| Grove, VE | 1 |
| Quintanilla, J | 1 |
| DeVaney, GT | 1 |
| Shoulson, I | 1 |
| Kartzinel, R | 1 |
| Chase, TN | 1 |
| Lenman, JA | 1 |
| Ferguson, IT | 1 |
| Fleming, AM | 1 |
| Herzberg, M | 1 |
| Robb, JE | 1 |
| Turnbull, MJ | 1 |
| Tan, BK | 1 |
| Leijnse-Ybema, HJ | 1 |
| Zee, MF | 1 |
| Bachman, DS | 1 |
| Butler, IJ | 1 |
| McKhann, GM | 1 |
| Pearce, I | 1 |
| Heathfield, KW | 1 |
| Pearce, MJ | 1 |
| Caraceni, T | 2 |
| Calderini, G | 1 |
| Consolazione, A | 1 |
| Riva, E | 1 |
| Algeri, S | 1 |
| Girotti, F | 2 |
| Spreafico, R | 1 |
| Branciforti, A | 1 |
| Dall'olio, A | 1 |
| Morselli, PL | 1 |
| Symington, GR | 1 |
| Leonard, DP | 1 |
| Shannon, PJ | 1 |
| Vajda, FJ | 1 |
| Perry, TL | 2 |
| Hansen, S | 1 |
| Giovannini, P | 1 |
| Avanzini, G | 1 |
| Schwarcz, R | 1 |
| Bennett, JP | 1 |
| Coyle, JT | 1 |
| Ikonen, E | 1 |
| Salo, A | 1 |
| Somer, M | 1 |
| Somer, H | 1 |
| Pääkkönen, L | 1 |
| Peltonen, L | 1 |
| Gram, L | 1 |
| Bentsen, KD | 1 |
4 reviews available for valproic acid and Huntington Disease
| Article | Year |
|---|---|
Degradation of misfolded proteins by autophagy: is it a strategy for Huntington's disease treatment?
Topics: Autophagy; Carbamazepine; Humans; Huntingtin Protein; Huntington Disease; Lithium; Mutant Proteins; | 2013 |
Epigenetic treatment of neurological disease.
Topics: Alzheimer Disease; Butylamines; Cell Differentiation; Endoplasmic Reticulum Stress; Epigenesis, Gene | 2011 |
Pharmacology of GABA.
Topics: 4-Aminobutyrate Transaminase; Anxiety Disorders; Autonomic Nervous System; Barbiturates; Benzodiazep | 1982 |
Valproate: an updated review.
Topics: Abnormalities, Drug-Induced; Brain Diseases; Chemical and Drug Induced Liver Injury; Coma; Dyskinesi | 1985 |
5 trials available for valproic acid and Huntington Disease
| Article | Year |
|---|---|
Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series.
Topics: Adult; Anticonvulsants; Dose-Response Relationship, Drug; Female; Humans; Huntington Disease; Hyperk | 2006 |
GABA and movement disorders.
Topics: Anticonvulsants; Baclofen; Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-Induced; | 1981 |
Huntington's disease: treatment with dipropylacetic acid and gamma-aminobutyric acid.
Topics: Adult; Aminobutyrates; Clinical Trials as Topic; Dopamine; Drug Evaluation; Drug Therapy, Combinatio | 1976 |
Sodium valproate in Huntington's chorea.
Topics: Clinical Trials as Topic; Drug Evaluation; Drug Tolerance; Female; Humans; Huntington Disease; Levod | 1976 |
Sodium valproate in Huntington's disease.
Topics: Adult; Arousal; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Huntington Disease; Middl | 1978 |
25 other studies available for valproic acid and Huntington Disease
| Article | Year |
|---|---|
Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.
Topics: Animals; Autophagy; Calcium Channels, L-Type; Clonidine; Cyclic AMP; Humans; Huntington Disease; Imi | 2008 |
Treatment of Behavioral Disinhibition in Huntington's Disease With Valproic Acid.
Topics: Aggression; Anticonvulsants; Female; Humans; Huntington Disease; Middle Aged; Problem Behavior; Valp | 2018 |
Rosiglitazone synergizes the neuroprotective effects of valproic acid against quinolinic acid-induced neurotoxicity in rats: targeting PPARγ and HDAC pathways.
Topics: Animals; Body Weight; Brain; Disease Models, Animal; Drug Synergism; Histone Deacetylase Inhibitors; | 2014 |
Preconditioning mesenchymal stem cells with the mood stabilizers lithium and valproic acid enhances therapeutic efficacy in a mouse model of Huntington's disease.
Topics: Animals; Antimanic Agents; Cytokines; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphopro | 2016 |
Pisa syndrome and parkinsonism secondary to valproic acid in Huntington's disease.
Topics: Aged; Anticonvulsants; Humans; Huntington Disease; Male; Parkinson Disease, Secondary; Sensation Dis | 2008 |
Identification of novel targets for PGC-1alpha and histone deacetylase inhibitors in neuroblastoma cells.
Topics: Apoptosis; Biological Transport; Caspase 3; Cell Line, Tumor; Enzyme Inhibitors; Fatty Acids; Gene E | 2009 |
Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; | 2009 |
Purmorphamine increases DARPP-32 differentiation in human striatal neural stem cells through the Hedgehog pathway.
Topics: Antigens, Differentiation; Brain; Brain-Derived Neurotrophic Factor; Bucladesine; Calbindin 2; Calbi | 2011 |
Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington's disease.
Topics: Affect; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination | 2011 |
Treating mouse models of Huntington disease.
Topics: Affect; Animals; Female; Huntington Disease; Lithium; Male; Valproic Acid | 2011 |
Serum carnitine levels and levocarnitine supplementation in institutionalized Huntington's disease patients.
Topics: Adult; Anticonvulsants; Carnitine; Databases, Factual; Diet; Dietary Supplements; Female; Hospitaliz | 2013 |
Huntington's disease and HDACi: would sulpiride and valproate be of therapeutic value?
Topics: Anticonvulsants; Antipsychotic Agents; Histone Deacetylases; Humans; Huntington Disease; Motor Activ | 2007 |
Myoclonus and Huntington's chorea: description of a case.
Topics: Adult; Clonazepam; Electroencephalography; Female; Humans; Huntington Disease; Myoclonus; Pedigree; | 1980 |
[Sleep in chronic chorea patients after therapy with sodium valproate].
Topics: Adult; Chorea; Chronic Disease; Female; gamma-Aminobutyric Acid; Humans; Huntington Disease; Male; M | 1984 |
Improvement of Huntington's disease with olanzapine and valproate.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Female; H | 2000 |
Sodium valproate in chorea.
Topics: Aged; Brain; Female; Gait; gamma-Aminobutyric Acid; Humans; Huntington Disease; Male; Movement; Vale | 1976 |
Sodium valproate in chorea.
Topics: Adult; Aged; Brain Chemistry; gamma-Aminobutyric Acid; Humans; Huntington Disease; Middle Aged; Vale | 1976 |
Long-term treatment of juvenile Huntington's chorea with dipropylacetic acid.
Topics: Child; Diseases in Twins; Female; Half-Life; Humans; Huntington Disease; Valerates; Valproic Acid | 1977 |
Valproate sodium in Huntington chorea.
Topics: Adolescent; Adult; Aged; Child; Female; Humans; Huntington Disease; Male; Middle Aged; Valerates; Va | 1977 |
Biochemical aspects of Huntington's chorea.
Topics: Adult; Age Factors; Blood Platelets; Brain Damage, Chronic; Dopamine; Dopamine beta-Hydroxylase; Fem | 1977 |
Isoniazid and Huntington's chorea.
Topics: Animals; Brain; gamma-Aminobutyric Acid; Humans; Huntington Disease; Isoniazid; Rats; Valproic Acid | 1978 |
Biochemical effects in man and rat of three drugs which can increase brain GABA content.
Topics: Acetates; Adult; Amino Acids; Aminobutyrates; Aminooxyacetic Acid; Animals; Brain; gamma-Aminobutyri | 1978 |
Pharmacology of Huntington's chorea. Personal experience.
Topics: Acetates; Adult; Aminobutyrates; Blood Cell Count; Bromocriptine; Female; gamma-Aminobutyric Acid; H | 1977 |
Inhibitors of GABA metabolism: implications for Huntington's disease.
Topics: 4-Aminobutyrate Transaminase; Alkynes; Aminocaproates; Aminocaproic Acid; Animals; Caudate Nucleus; | 1977 |
Terminal deletion of chromosome 4p (4p16.3) shows a breakpoint between loci linked to Huntington disease.
Topics: Abnormalities, Multiple; Adolescent; Chromosome Banding; Chromosome Deletion; Chromosomes, Human, Pa | 1992 |